CD274 and neoplasm: The immune‐inflamed status of tumors is evaluated on the basis of the immunoreactivity of PD‐1/PD‐L1 in inflammatory and tumor cells as well as histological evaluations, including the presence of tumor‐associated immune cells (TAICs) and tumor‐infiltrating lymphocytes, which are related to ICI efficacy and poor patient outcomes [16].